SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis
FRA:SRT3 - Deutsche Boerse Ag - DE0007165631 - Currency: EUR
We assign a fundamental rating of 3 out of 10 to SRT3. SRT3 was compared to 18 industry peers in the Life Sciences Tools & Services industry. SRT3 has a bad profitability rating. Also its financial health evaluation is rather negative. SRT3 is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SRT3 was profitable.
SRT3 had a positive operating cash flow in the past year.
In the past 5 years SRT3 has always been profitable.
Each year in the past 5 years SRT3 had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of 0.94%, SRT3 is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
SRT3's Return On Equity of 3.52% is on the low side compared to the rest of the industry. SRT3 is outperformed by 72.22% of its industry peers.
The Return On Invested Capital of SRT3 (3.51%) is worse than 77.78% of its industry peers.
SRT3 had an Average Return On Invested Capital over the past 3 years of 8.34%. This is in line with the industry average of 6.90%.
The last Return On Invested Capital (3.51%) for SRT3 is well below the 3 year average (8.34%), which needs to be investigated, but indicates that SRT3 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.94% | ||
| ROE | 3.52% | ||
| ROIC | 3.51% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
1.3 Margins
Looking at the Profit Margin, with a value of 2.77%, SRT3 is doing worse than 77.78% of the companies in the same industry.
In the last couple of years the Profit Margin of SRT3 has declined.
SRT3's Operating Margin of 11.82% is on the low side compared to the rest of the industry. SRT3 is outperformed by 66.67% of its industry peers.
In the last couple of years the Operating Margin of SRT3 has declined.
The Gross Margin of SRT3 (45.27%) is better than 77.78% of its industry peers.
SRT3's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.82% | ||
| PM (TTM) | 2.77% | ||
| GM | 45.27% |
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SRT3 is still creating some value.
SRT3 has more shares outstanding than it did 1 year ago.
SRT3 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SRT3 has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.13 indicates that SRT3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of SRT3 (2.13) is worse than 66.67% of its industry peers.
The Debt to FCF ratio of SRT3 is 6.50, which is on the high side as it means it would take SRT3, 6.50 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 6.50, SRT3 is doing worse than 72.22% of the companies in the same industry.
SRT3 has a Debt/Equity ratio of 1.55. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.55, SRT3 is doing worse than 88.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.55 | ||
| Debt/FCF | 6.5 | ||
| Altman-Z | 2.13 |
ROIC/WACC0.47
WACC7.49%
2.3 Liquidity
A Current Ratio of 1.46 indicates that SRT3 should not have too much problems paying its short term obligations.
With a Current ratio value of 1.46, SRT3 perfoms like the industry average, outperforming 44.44% of the companies in the same industry.
SRT3 has a Quick Ratio of 1.46. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
SRT3 has a Quick ratio of 0.93. This is in the lower half of the industry: SRT3 underperforms 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.46 | ||
| Quick Ratio | 0.93 |
3. Growth
3.1 Past
The earnings per share for SRT3 have decreased strongly by -36.23% in the last year.
SRT3 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -11.87% yearly.
Looking at the last year, SRT3 shows a small growth in Revenue. The Revenue has grown by 3.99% in the last year.
The Revenue has been growing by 13.10% on average over the past years. This is quite good.
EPS 1Y (TTM)-36.23%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%30.97%
Revenue 1Y (TTM)3.99%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%7.74%
3.2 Future
The Earnings Per Share is expected to grow by 20.15% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 8.92% on average over the next years. This is quite good.
EPS Next Y22.89%
EPS Next 2Y24.43%
EPS Next 3Y26.21%
EPS Next 5Y20.15%
Revenue Next Year6.37%
Revenue Next 2Y7.98%
Revenue Next 3Y8.7%
Revenue Next 5Y8.92%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 47.65, the valuation of SRT3 can be described as expensive.
SRT3's Price/Earnings ratio is a bit more expensive when compared to the industry. SRT3 is more expensive than 72.22% of the companies in the same industry.
SRT3's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.29.
Based on the Price/Forward Earnings ratio of 32.06, the valuation of SRT3 can be described as expensive.
Based on the Price/Forward Earnings ratio, SRT3 is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.17, SRT3 is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.65 | ||
| Fwd PE | 32.06 |
4.2 Price Multiples
SRT3's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. SRT3 is more expensive than 66.67% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SRT3 is valued a bit cheaper than 61.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.39 | ||
| EV/EBITDA | 22.95 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
SRT3's earnings are expected to grow with 26.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.08
PEG (5Y)N/A
EPS Next 2Y24.43%
EPS Next 3Y26.21%
5. Dividend
5.1 Amount
With a yearly dividend of 0.42%, SRT3 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.87, SRT3 has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.38, SRT3's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.42% |
5.2 History
The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
SRT3 pays out 53.09% of its income as dividend. This is a bit on the high side, but may be sustainable.
SRT3's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP53.09%
EPS Next 2Y24.43%
EPS Next 3Y26.21%
FRA:SRT3 (6/3/2025, 3:13:37 PM)
203.45
-1.55 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners2.79%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap15.23B
Analysts77.14
Price Target357.73 (75.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.42% |
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP53.09%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.1%
Min EPS beat(2)-4.13%
Max EPS beat(2)-4.06%
EPS beat(4)1
Avg EPS beat(4)-0.94%
Min EPS beat(4)-22.4%
Max EPS beat(4)26.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.77%
Min Revenue beat(2)2.67%
Max Revenue beat(2)4.87%
Revenue beat(4)3
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-4.07%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.58%
PT rev (3m)-4.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)-0.28%
Revenue NY rev (3m)-1.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.65 | ||
| Fwd PE | 32.06 | ||
| P/S | 4.42 | ||
| P/FCF | 21.39 | ||
| P/OCF | 14.24 | ||
| P/B | 5.62 | ||
| P/tB | N/A | ||
| EV/EBITDA | 22.95 |
EPS(TTM)4.27
EY2.1%
EPS(NY)6.35
Fwd EY3.12%
FCF(TTM)9.51
FCFY4.68%
OCF(TTM)14.29
OCFY7.02%
SpS45.99
BVpS36.19
TBVpS-35.83
PEG (NY)2.08
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.94% | ||
| ROE | 3.52% | ||
| ROCE | 4.72% | ||
| ROIC | 3.51% | ||
| ROICexc | 3.9% | ||
| ROICexgc | 12.82% | ||
| OM | 11.82% | ||
| PM (TTM) | 2.77% | ||
| GM | 45.27% | ||
| FCFM | 20.68% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexcg growth 3Y-35.26%
ROICexcg growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.55 | ||
| Debt/FCF | 6.5 | ||
| Debt/EBITDA | 5.06 | ||
| Cap/Depr | 84.42% | ||
| Cap/Sales | 10.39% | ||
| Interest Coverage | 1.93 | ||
| Cash Conversion | 128.78% | ||
| Profit Quality | 745.86% | ||
| Current Ratio | 1.46 | ||
| Quick Ratio | 0.93 | ||
| Altman-Z | 2.13 |
F-Score7
WACC7.49%
ROIC/WACC0.47
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)-36.23%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%30.97%
EPS Next Y22.89%
EPS Next 2Y24.43%
EPS Next 3Y26.21%
EPS Next 5Y20.15%
Revenue 1Y (TTM)3.99%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%7.74%
Revenue Next Year6.37%
Revenue Next 2Y7.98%
Revenue Next 3Y8.7%
Revenue Next 5Y8.92%
EBIT growth 1Y-9.05%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year103.14%
EBIT Next 3Y38.58%
EBIT Next 5Y26.44%
FCF growth 1Y303.11%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y44.89%
OCF growth 3Y4.07%
OCF growth 5Y20.79%